Analysis of survival of patients with NTRK fusion-positive tumors using larotrectinib

Larotrectinib (Larotrectinib), this targeted therapy drug for NTRK gene fusion-positive tumors, has attracted much attention since its introduction. Many patients and their families are concerned about one question: How long can they live taking larotrectinib?

It must be clear that larotrectinib has a significant effect on improving the survival rate of patients with NTRK gene fusion-positive tumors. However, the specific survival period of patients varies from person to person and is affected by many factors.

Judging from clinical data, larotrectinib has shown encouraging efficacy in patients with NTRK gene fusion-positive solid tumors. In multiple clinical trials, approximately 75% of patients experienced partial or complete responses with larotrectinib. What is even more exciting is that some patients can even maintain long-term progression-free survival, with the average progression-free survival (PFS) reaching more than 2 years.

Lifetime is not static. It is affected by multiple factors such as tumor type, stage, patient age, timing of treatment, severity of illness, and overall health. For example, certain tumor types such as neuroblastoma, thyroid cancer, and soft tissue sarcoma are more sensitive to larotrectinib. Patients who are detected early and are positive for NTRK gene fusion often have better therapeutic effects.

Individual differences among patients cannot be ignored. Younger patients versus older patients, and those in good health versus those with other comorbidities, may have significantly different responses to larotrectinib. In addition, drug resistance during treatment is also an important factor affecting survival. Some patients may develop drug resistance after long-term treatment, resulting in reduced efficacy.

Although larotrectinib has a significant effect on patients with NTRK fusion-positive tumors and can effectively prolong survival, the specific survival period of each patient varies. In order to ensure the continuity and effectiveness of treatment, patients should undergo treatment under the guidance of a doctor and have regular follow-up visits to evaluate the efficacy. At the same time, maintaining a positive and optimistic attitude and cooperating with treatment is also one of the important factors in prolonging survival.

xa0

Reference materials:

1.New England Journal of Medicine (NEJM):https://www.nejm.org

2.The official website of the U.S. Food and Drug Administration (FDA):https://www.fda.gov